Patent ID: 8178098
Filing Date: 2012-05-15
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method to reduce airway hyperresponsiveness in a mammal that has, or is at risk of developing, airway hyperresponsiveness, comprising administering to the lungs of said mammal an aerosolized antibody formulation comprising antibodies that selectively bind to a receptor on a T cell selected from the group consisting of: a T cell antigen receptor (TCR) selected from the group consisting of an αβ TCR and a γδ TCR, CD3, CD4 and CD8, wherein the binding of the antibodies to the receptor causes the depletion or inactivation of the T cell, wherein administration of the antibody formulation reduces airway hyperresponsiveness in said mammal; wherein said aerosolized antibody formulation is administered at a dose of less than about 1 μg×kilogram wherein the administration of the aerosolized antibody formulation affects pulmonary T cell responses in the mammal, while peripheral T cell responses in the mammal are neither substantially stimulated nor substantially inhibited.